|
27 Aug 2009 |
UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE)
|
|
27 Aug 2009 |
START OF THE FIRST PHASE II CLINICAL TRIAL WITH MONOCLONAL ANTIBODY IPH 2101 SUPPORTED BY A NEW 2.9 MILLIONS EUROS FINANCING FROM OSEO
|
|
26 Aug 2009 |
GENMAB ANNOUNCES POSITIVE TOP-LINE RESULTS FOR ARZERRA™ IN FRONT LINE NHL
|
|
26 Aug 2009 |
Dyax Announces Developments in Licensing and Funded Research Program
|
|
24 Aug 2009 |
Lpath Achieves Merck Serono Milestone
|
|
24 Aug 2009 |
Novartis receives approval in EU for Xolair® to treat children age 6 to 11 years suffering from severe persistent allergic asthma
|
|
24 Aug 2009 |
Seattle Genetics Completes Enrollment of Brentuximab Vedotin (SGN-35) Pivotal Trial for Patients with Hodgkin Lymphoma
|
|
18 Aug 2009 |
Crucell Receives NIH Award for the Development of Influenza Monoclonal Antibodies
|
|
18 Aug 2009 |
GLAXOSMITHKLINE AND GENMAB ANNOUNCE RESULTS FROM A STUDY OF ARZERRA IN RITUXIMAB REFRACTORY FOLLICULAR NHL
|
|
18 Aug 2009 |
Neurimmune Therapeutics Announces Advancement of Alzheimer’s Program into Preclinical Development
|
|
18 Aug 2009 |
Lpath Completes Enrollment of Patients in iSONEP(TM) Phase 1 Clinical Trial
|
|
17 Aug 2009 |
Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
|
|
17 Aug 2009 |
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
|
|
14 Aug 2009 |
Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
|
|
14 Aug 2009 |
Immunomedics Announces FDA Allowance of Investigational New Drug Application for Milatuzumab-Doxorubicin Conjugate
|
|
11 Aug 2009 |
BioInvent Announces Approval to start Phase I Trial for BI-505 in Multiple Myeloma
|
|
11 Aug 2009 |
GENMAB ANNOUNCES PRELIMINARY TOP-LINE RESULTS FOR ARZERRA™ IN FRONT LINE CLL
|
|
10 Aug 2009 |
MedImmune Advances Three Oncology Programs Into the Clinic
|
|
09 Aug 2009 |
Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
|
|
07 Aug 2009 |
Antisoma announces discontinuation of development of AS1402
|
|
05 Aug 2009 |
FDA: Cancer Warnings Required for TNF Blockers
|
|
05 Aug 2009 |
PharmaGap Releases Results of Initial Testing For Novel Cancer Drug Compound at the Ottawa Hospital Research Institute
|
|
04 Aug 2009 |
Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
|
|
04 Aug 2009 |
Facet Biotech Announces Daclizumab Program in Multiple Sclerosis to Advance
|
|
03 Aug 2009 |
Merck KGaA Presented New Data On the Combination of Erbitux with Standard First-Line Therapy in Patients with NSCLC
|
